IMPI Alters Linkage Gazette: Shift from “Relevant Claims” to Full

If you’ve ever tried to assemble IKEA furniture without the instructions, you already understand the vibe of patent-linkage compliance on a bad day:
a lot of pieces, a lot of confidence, and then one mysterious screw left over that haunts you forever.

Now imagine the instruction manual got replaced with a link to every manual ever written for that product line, in every edition, including the one
where someone decided to add a fold-out diagram the size of a dining table. That, in a nutshell, is what many stakeholders are feeling after IMPI’s
recent change to Mexico’s Linkage Gazette: a shift away from publishing selected “relevant claims” toward linking out to the full Letters Patent.

This article breaks down what changed, why it matters, who wins (spoiler: coffee vendors), and how pharma and life-sciences teams can adjust their
regulatory and IP strategies without turning every filing season into a group therapy session.

What the Linkage Gazette Is (In Plain English)

The IMPI–COFEPRIS handshake

Mexico’s patent linkage framework is designed to reduce the odds that a generic (or biosimilar) marketing authorization slips through while a valid
pharmaceutical patent is still standing guard. The system is built around coordination between:

• IMPI (Mexico’s industrial property office), which handles patents; and
• COFEPRIS (Mexico’s health regulatory authority), which handles marketing authorizations.

A key tool in the process is the Linkage Gazette (often referred to in English as the Medicines Gazette or Gazette for Medicaments):
a periodic publication that lists certain in-force patents considered relevant to allopathic medicines. In theory, the Gazette helps regulators and applicants
quickly identify patents that might be implicated during the approval process.

Why “relevant claims” existed in the first place

Patents are made of claims, and claims are where the legal action lives. But patents can have a lot of claimssometimes dozens, sometimes a small novel’s
worth if you include dependencies, variations, and “just-in-case” drafting.

Historically, publishing “relevant claims” inside the Linkage Gazette worked like a highlight reel: it surfaced the portions of a patent
most likely to matter for a linkage review, rather than forcing everyone to wade through the entire claim set. It wasn’t perfect, but it was efficient.
And in regulatory workflows, efficiency is basically a love language.

The Big Change: From Excerpts to Full Patent Text

What actually changed (and why people noticed)

In the newer approach, the Gazette no longer reproduces the most “relevant claims.” Instead, it provides a link that redirects readers to the
complete Letters Patentmeaning anyone performing a linkage assessment may need to consult and analyze the entire granted claim set, not just curated excerpts.

From a distance, this can look like a simple formatting tweakless text in the Gazette, more reliance on linked documents. In practice, it changes the
workflow, the time burden, and the risk calculus across the board.

Why this is more than a “layout update”

Moving from “relevant claims” to full-patent access sounds like it should increase transparency. But it can also create a paradox:
more information can mean less clarity. Here’s why:

• Scope ambiguity grows: When only a subset is published, stakeholders are guided toward likely linkage-relevant boundaries.
  When everything is on the table, it can be unclear which claims are meant to drive the linkage analysis.
• Time-to-assess increases: Full-claim review takes longer, especially for patents with heavy dependency chains or broad claim families.
• Regulatory friction rises: Applicants and reviewers must spend more time building claim charts and mapping product features to claim
  elementsoften under tight timelines.
• Disputes become more “technical”: If a denial or suspension hinges on a claim interpretation buried deep in the claim set,
  the path to appeal or challenge can get more complicated.

Who Feels the Impact (Hint: Almost Everyone)

Patent holders: more coverage, but also more responsibility

Patent owners may appreciate that full text is available, because it reduces arguments about whether the “wrong” subset of claims was shown.
If the whole patent is accessible, the owner can point to the full claim set and say, “It’s all right there.”

The tradeoff is that owners may need to be more proactive about defining what is truly linkage-relevant. If regulators and applicants are staring at the
entire patent, owners can’t assume everyone will magically focus on the best claim. Good linkage strategy increasingly means:
selecting, explaining, and substantiating the claims that matter most.

Generic and biosimilar applicants: welcome to the full-claims gym

For applicants, the most immediate change is workload. Instead of reviewing a small set of published claims, teams may need to analyze:
independent claims, dependent claim trees, and sometimes multiple patents in a familythen translate that into a risk position that can survive regulatory
scrutiny.

The practical effect is that freedom-to-operate analysis and regulatory filing strategy become even more intertwined. If you used to treat linkage review as
a quick checkpoint, the new reality pushes it closer to a mini patent-clearance exercise.

Regulators: more reading, more pressure, more room for criticism

Regulators are not paid by the claim. (If they were, they’d all own beach houses.) A system that implicitly expects broader claim review can amplify
pressure on review timelines and consistency, especially when multiple stakeholders interpret “what counts” differently.

And with complexity comes a familiar regulatory risk: if decisions feel opaque or inconsistent, the system invites criticismeither for
being too restrictive (blocking competition) or not restrictive enough (failing to protect valid patents).

How This Fits with the Broader 2025–2026 Linkage Trend

A system that’s evolving (not standing still)

The “full patent” pivot didn’t happen in a vacuum. In recent years, Mexico’s linkage ecosystem has been in a state of active refinement,
shaped by legal reforms, policy discussions, and stakeholder pressure around transparency, notice, and alignment with trade obligations.

One practical takeaway: teams should treat the Linkage Gazette as a living instrument, not a static list. Processes that were “good enough” two
years ago may now be underpowered.

Guidelines, collaboration mechanics, and the paperwork reality

Collaboration mechanisms between IMPI and COFEPRIS have been the subject of ongoing clarification efforts. As these mechanisms mature, the information
exchanged and the way it is presented can have downstream effects on who must do whatand when.

The shift to full Letters Patent access, in that context, can be read as an attempt to standardize what the Gazette provides (a pathway to the official
patent text) while leaving the “relevance filtering” to the analysis stage. That may be defensible from a formalist perspective, but it shifts
the burden to the people actually trying to make decisions with real deadlines.

Practical Playbook: How to Stay Sane Under Full-Patent Review

1) Build a “claim map” library before you need it

If you wait until a filing deadline to build claim charts, you will eventually discover a new medical condition: acute spreadsheet fatigue.
Instead, build a living library:

• Core product feature map: a standardized list of API, salts, polymorphs, formulation features, dosage forms, indications, and routes.
• Patent claim element map: key limitations extracted from independent claims, with dependencies grouped logically.
• Risk notes: claim interpretation assumptions, known prosecution-history issues, and any litigation signals.

This turns full-patent access from a time sink into a structured process. Your future self will thank you, probably with tears.

2) Recreate “relevant claims” internally (without pretending the old days are coming back)

Even if the Gazette no longer publishes relevant excerpts, you can create an internal relevance filter:

• Start with independent claims that plausibly read on the approved product profile.
• Identify dependent claims that add the exact features your product includes (or intentionally avoids).
• Document why a claim is in-scope or out-of-scope using plain language and claim-element logic.

In other words: treat “relevant claims” as a workflow concept, not a Gazette formatting feature.

3) Track the Gazette like it’s earnings season

The Linkage Gazette is typically published on a recurring schedule, and extraordinary editions can also appear. Don’t rely on surprise discovery.
Set up:

• Monitoring cadence: regular checks around expected publication windows.
• Change logs: what was added, removed, or altered (including how patent access is presented).
• Ownership and licensing notes: who owns what, who is licensed, and what that means for regulatory status.

The goal is to avoid the classic internal email: “Wait, when did this patent get listed?” (Usually right after you filed.)

4) Treat documentation as a strategic asset

When the process becomes more complex, the record becomes more important. Whether you are a patent holder advocating relevance or an applicant arguing
non-infringement, build a clean file that can survive:

• regulatory questions,
• internal audits,
• and, if things get spicy, litigation or administrative challenges.

Full-patent review doesn’t just increase readingit increases the number of places where a misunderstanding can snowball. Documentation is your
snowplow.

Specific Scenarios: What “Full Claims” Looks Like in the Wild

Scenario 1: The “clean” API patent (the unicorn)

A straightforward compound patent with a handful of claims is the best-case scenario. Full text access doesn’t hurt much because the claim set is
small, the boundaries are clear, and mapping is manageable. In these cases, the new approach may even reduce disputes about whether a claim excerpt
was cherry-picked.

Scenario 2: Formulation patents with dense dependency trees (the treadmill)

Now picture a formulation patent where the independent claim is broad and the dependent claims progressively narrow into very specific excipient ranges,
particle sizes, dissolution profiles, or dosing regimens. Under a relevant-claims model, you might have seen the key claim that regulators tend to focus on.
Under full-patent access, you have to decide which claim matters mostthen justify it.

This is where claim mapping earns its keep. Teams that can quickly isolate the “decision-driving” claim limitations will move faster and argue more
coherently.

Scenario 3: Expanding categories (including medical-use discussions)

Stakeholders have also watched how the system handles different patent categories over time, including debates about whether and how certain claim types
should appear in linkage publications. When categories expand or are handled through extraordinary publications, the practical lesson is the same:
your analysis playbook must be flexible.

What to Watch Next

• Operational guidance: whether agencies issue clarifications about how reviewers should focus their claim analysis under full-patent access.
• Consistency signals: whether decisions cluster around specific claim types or drift across broader interpretations.
• Stakeholder pushback: criticism can arise from both sideseither that the system is too burdensome or not protective enough.
• Process refinements: additional rules, forms, or procedural tweaks that change timelines and evidentiary expectations.

Conclusion

IMPI’s shift in the Linkage Gazettefrom publishing “relevant claims” to linking to full Letters Patentchanges the daily reality of patent linkage in
Mexico. It can increase transparency while simultaneously increasing complexity, because “more information” is not the same as “better signal.”

The winners will be the teams who turn full-text access into structured analysis: claim maps, relevance filters, disciplined documentation, and proactive
monitoring. The losers will be anyone who treats this like a cosmetic change and discoversright before a filingthat the “quick check” has become
a full workout.

The good news: with the right internal playbook, the full-patent model can be manageable, defensible, and even strategically useful. The bad news:
you may need a larger coffee budget line item. (Call it “compliance fuel.”)

Field Notes: of Real-World Experience Around the Shift

In practice, the move from “relevant claims” to full patent text doesn’t feel like a single policy changeit feels like a chain reaction inside
organizations that were calibrated for speed. The first week after a new Gazette format drops, the same pattern tends to repeat across companies:
someone in regulatory affairs forwards a screenshot with a message like, “Are we supposed to click these now?” Someone in IP replies, “We
always clicked them.” Then a third person (usually the project manager) asks the only question that matters: “How long will this take?”
And suddenly everyone realizes they were using different definitions of “review.”

The most successful teams treat the change as a workflow redesign, not an emergency. They create a simple, repeatable triage system. First, they
classify patents by practical risk: (1) clear API coverage, (2) plausible formulation overlap, (3) peripheral or speculative relevance, and (4) likely not
relevant. That classification is not a legal conclusion; it’s a scheduling tool. It decides whether the first-pass reviewer is a patent analyst, an
in-house counsel, or a cross-functional group that includes both legal and scientific voices.

The next lesson is surprisingly human: full-text review increases the number of “false alarms”claims that look scary until someone translates
them into product reality. A dependent claim that adds an excipient range might read like a trap, but it may be irrelevant if the product uses a different
stabilizer or a different release profile. Under the old excerpt model, fewer people saw those claims, so fewer people panicked. Under the full model,
everyone sees everything, and panic becomes more democratic.

A practical fix is the “two-layer memo.” Layer one is a one-page plain-English summary for non-patent readers: what the patent covers, what
claim elements matter, and why the product likely does or does not touch them. Layer two is the detailed claim chart for the experts who want every
limitation mapped. This keeps meetings from turning into interpretive readings of dependent claim 27 while the clock is ticking.

Finally, teams that thrive under the new approach invest in consistency. They standardize terminology (API vs. salt vs. polymorph), track assumptions
(which claim construction choices were used), and store prior analyses so the next Gazette cycle doesn’t start from scratch. In a full-patent world,
the competitive advantage isn’t just legal brillianceit’s operational muscle: the ability to turn hundreds of lines of claims into a clear,
defensible position before anyone runs out of caffeine or calendar.